Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.

Slides:



Advertisements
Similar presentations
Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.
Advertisements

PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade Findings of the ESPRIT Trial James E.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48 Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin.
TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.
Jacqueline Saw, MD*, Danielle Brennan, MS †, Steven Steinhubl, MD ‡, Deepak L. Bhatt, MD †, Koon-Hou Mak, MD §, Keith Fox, MB^, and Eric J. Topol, MD #
Point of Care Platelet Function Testing – Is There Still Value?
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter? Steven R. Steinhubl, Frederick Feit, Antonio.
The Influence of Proton Pump Inhibitors on Clinical Outcomes After Successful Percutaneous Coronary Intervention Kishore J. Harjai, MD, FACC Chetan Shenoy,
Enoxaparin – Future Prospects in Cardiovascular Diseases David Hasdai, MD Rabin Medical Center Tel Aviv University.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
New Horizons for Patients with ST-Elevation Myocardial Infarction Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Implications of Preoperative Thienopyridine Use Prior to Coronary Bypass Graft Surgery: A Report from the ACUITY Trial Ramin Ebrahimi, MD University of.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
AHA 2011 Late Breaking Trials Synthesis and Critical Review.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial J Am Coll Cardiol 2007;50:291-5 Jacqueline Saw, MD*, Danielle Brennan, MS†,
Robert A. Harrington, MD Professor of Medicine
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Gregg W. Stone MD for the ACUITY Investigators
The American College of Cardiology Presented by Dr. Adnan Kastrati
MCV Campus Ginger Edwards.
Revascularization in Patients With Left Ventricular Dysfunction:
Insight into the Gauging Responsiveness with A VerifyNow Assay - Impact on Thrombosis And Safety (GRAVITS) Trial Peter Berger, MD Director, Center for.
Should We Preload STEMI Patients with Antiplatelet Therapy?
For the HORIZONS-AMI Investigators
Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial.
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
The GRAVITAS trial Matthew J. Price MD, FACC, FSCAI
Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial Steven.
Radial vs Femoral Access in ACS Patients
Sunil V. Rao MD The Duke Clinical Research Institute
Dr. Harvey White on behalf of the ACUITY investigators
Giuseppe Biondi Zoccai University of Turin, Turin, Italy
Would you recommend extending DAPT >1 year post-MI?
For the HORIZONS-AMI Investigators
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
% Heparin + GPI IIb/IIIa Bivalirudin +
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
Erasmus MC, Thoraxcenter
Implications of Preoperative Thienopyridine Use
on behalf of the ACUITY investigators
What oral antiplatelet therapy would you choose?
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Update on the New Antiplatelet Agents:
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients
Baseline Characteristics
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
Section C: Clinical trial update: Oral antiplatelet therapy
Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death
Presentation transcript:

Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.

Inhibition of Platelet Aggregation Following Clopidogrel Administration Hochholzer W et al. Circulation. 2005;111

Clopidogrel Loading Dose Timing and Risk of MACE Log Odds of Death, MI or UTVR at 28 Days Placebo - 2 Clopidogrel P = 0.020 for treatment / timing interaction - 3 - 4 - 5 - 6 5 10 15 20 25 30 Hours Prior to PCI of Study Drug Loading Dose J Am Coll Cardiol 2006;47:939–43.

30 Day Primary Endpoint Adverse Events Influence of Thienopyridine Exposure – PCI pts 30 Day Primary Endpoint Adverse Events RR [95%CI] 0.81 (0.68-0.96) RR [95%CI] 0.96 (0.77-1.20) RR [95%CI] 0.50 (0.37-0.67) RR [95%CI] 1.07 (0.83-1.39) RR [95%CI] 1.37 (1.00-1.88) RR [95%CI] 0.61 (0.39-0.97) Thienopyridine Exposed Not Thienopyridine Exposed

CURE: Major Bleeding in CABG Patients Major or life-threatening bleeding w/in 7 days of CABG P=0.07 P=0.53 Clopidogrel stopped <5 days prior to CABG >5 days K.Fox et al, ESC 2002

ACUITY: Primary Outcomes in CABG Patients Patients with and without a thienopyridine administered in-hospital prior to CABG P=0.066 P=0.013 P=0.362 *Heparin=unfractionated or enoxaparin

30 Day Outcomes – CABG Patients by Thienopyridine Status Patients with and without a thienopyridine administered in-hospital prior to CABG Thieno (+) n=718 Thieno (-) n=820 P-value Resource Utilization Total LOS, median 12.1 9.0 <0.001 Pre-CABG LOS, median 4.6 2.5 Post-CABG LOS, median 6.9 5.8 Bleeding Endpoints Post CABG Major Bleeding 50.0% 50.5% 0.85 Post CABG Blood transfusions 38.2% 38.0% 0.96 24hr Chest Tube Output (median) 600.0 ml 550.0 ml 0.22